24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Mori Arkin
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:36
Palo Alto Networks founder Nir Zuk in talks to acquire TV station
15:25
SolarEdge appoints new CEO amid ongoing restructuring efforts
14:57
SentinelOne shares plummet as it faces competitive headwinds despite revenue growth
12:10
Tech boom sees six new Israelis join billionaires list
More stories
Buzz
Most popular
Daily
Weekly
1
Tech boom sees six new Israelis join billionaires list
2
Michael Levitt Analysis: Corona Is Slowing Down, Humanity Will Survive
3
Palo Alto Networks founder Nir Zuk in talks to acquire TV station
4
Who will be Intel’s next CEO? Srouji, Murphy, and Tan lead the pack
5
The Gili Ra’anan model: Questions emerging from Cyberstarts' remarkable success
More news
Mori Arkin
5 stories about Mori Arkin
Exalenz Bioscience Acquired for $49M
19.02.20
|
Golan Hazani
Israeli-born billionaire & biomed entrepreneur Mori Arkin sold his company for 6.10 NIS per share. Learn more on CTech!
Biomed Entrepreneur Mori Arkin Nearing Sale of Exalenz to a U.S. Company
19.02.20
|
Golan Hazani
Tel Aviv-listed Exalenz is not considered one of the serial entrepreneur’s great successes, having lost 73% of its valuation over the past five years. The current deal will see it sold at a premium of tens of percentages, according to one source
Merck and WuXi AppTec Announce Launch of Biotech Incubator in Israel
20.02.18
|
Meir Orbach
The incubator program has a five year budget of 20 million euros
Acne Cream Developer Sol-Gel files for $86 Million Nasdaq IPO
31.08.17
|
Dror Reich
The clinical-stage drug developer will remain a "controlled company" under current shareholder Arkin Dermatology
Anti-Acne Drug Developer Plans Nasdaq IPO
15.08.17
|
Golan Hazani
Sol-Gel approached potential underwriters. It aims to go public before the end of the year
Please ensure Javascript is enabled for purposes of
website accessibility